gemcitabine has been researched along with yttrium radioisotopes in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cardillo, TM; Gold, DV; Modrak, D; Schutsky, K | 1 |
| Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K | 1 |
| Chang, CH; Gold, DV; Goldenberg, DM; Karacay, H; McBride, WJ; Ragland, DR; Rossi, EA; Sharkey, RM | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M | 1 |
| Higashi, T; Koizumi, M; Kurosawa, G; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y | 1 |
| Ahmed, O; Baker, T; Fung, J; Hwang, G; Liao, CY; Patel, M; Pillai, A; Yu, Q | 1 |
2 trial(s) available for gemcitabine and yttrium radioisotopes
| Article | Year |
|---|---|
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
6 other study(ies) available for gemcitabine and yttrium radioisotopes
| Article | Year |
|---|---|
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Radioimmunotherapy; Time Factors; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental; Organometallic Compounds; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Oligopeptides; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2009 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Topics: Animals; Antibodies, Monoclonal; Basigin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 2018 |
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Cisplatin; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2023 |